Artivion (NYSE:AORT – Free Report) had its price target decreased by Needham & Company LLC from $58.00 to $44.00 in a report issued on Friday,Benzinga reports. Needham & Company LLC currently has a buy rating on the stock.
Other equities research analysts have also issued reports about the company. Weiss Ratings raised Artivion from a “sell (d)” rating to a “hold (c-)” rating in a research report on Friday, February 20th. Canaccord Genuity Group dropped their price target on Artivion from $51.00 to $48.00 and set a “buy” rating on the stock in a research report on Friday, February 13th. Stifel Nicolaus set a $55.00 price objective on Artivion in a report on Thursday, March 5th. Wall Street Zen lowered shares of Artivion from a “buy” rating to a “hold” rating in a research note on Saturday, April 25th. Finally, LADENBURG THALM/SH SH raised shares of Artivion from a “neutral” rating to a “buy” rating and set a $42.00 target price on the stock in a research report on Friday, April 10th. Seven analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $47.83.
Artivion Price Performance
Artivion (NYSE:AORT – Get Free Report) last issued its earnings results on Thursday, May 7th. The company reported $0.08 EPS for the quarter, topping analysts’ consensus estimates of $0.06 by $0.02. The business had revenue of $116.34 million for the quarter, compared to analyst estimates of $115.69 million. Artivion had a net margin of 2.55% and a return on equity of 7.21%. The company’s quarterly revenue was up 17.5% compared to the same quarter last year. During the same period last year, the company posted ($0.01) earnings per share. On average, research analysts forecast that Artivion will post 0.63 earnings per share for the current year.
Insider Buying and Selling
In related news, SVP Jean F. Holloway sold 8,962 shares of the company’s stock in a transaction on Wednesday, March 4th. The stock was sold at an average price of $38.00, for a total transaction of $340,556.00. Following the completion of the sale, the senior vice president directly owned 185,095 shares in the company, valued at $7,033,610. This represents a 4.62% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, CEO James P. Mackin sold 20,962 shares of the firm’s stock in a transaction dated Monday, February 23rd. The shares were sold at an average price of $37.59, for a total value of $787,961.58. Following the sale, the chief executive officer directly owned 780,031 shares in the company, valued at approximately $29,321,365.29. The trade was a 2.62% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders sold 133,043 shares of company stock valued at $4,977,158. 6.30% of the stock is currently owned by insiders.
Institutional Inflows and Outflows
Several large investors have recently modified their holdings of the company. Vanguard Group Inc. boosted its stake in Artivion by 4.7% in the fourth quarter. Vanguard Group Inc. now owns 3,170,089 shares of the company’s stock valued at $144,588,000 after acquiring an additional 141,030 shares in the last quarter. Morgan Stanley grew its holdings in Artivion by 0.8% in the fourth quarter. Morgan Stanley now owns 2,256,742 shares of the company’s stock worth $102,930,000 after purchasing an additional 18,248 shares during the last quarter. State Street Corp increased its position in shares of Artivion by 2.9% during the fourth quarter. State Street Corp now owns 1,584,920 shares of the company’s stock worth $72,288,000 after purchasing an additional 44,641 shares in the last quarter. Fred Alger Management LLC lifted its holdings in shares of Artivion by 4.2% during the 4th quarter. Fred Alger Management LLC now owns 1,372,572 shares of the company’s stock valued at $62,603,000 after purchasing an additional 55,322 shares during the last quarter. Finally, Conestoga Capital Advisors LLC purchased a new stake in shares of Artivion during the 1st quarter valued at $43,044,000. Institutional investors own 86.37% of the company’s stock.
Trending Headlines about Artivion
Here are the key news stories impacting Artivion this week:
- Positive Sentiment: Artivion reported Q1 2026 revenue of $116.3 million, up 18% year over year, and adjusted EPS of $0.08, topping analyst estimates. Artivion Reports First Quarter 2026 Financial Results and Announces Exercise of Option to Acquire Endospan
- Positive Sentiment: Adjusted EBITDA rose 26% to $22.1 million, showing improving profitability as the company grows. Artivion Reports First Quarter 2026 Financial Results and Announces Exercise of Option to Acquire Endospan
- Positive Sentiment: The FDA approved the NEXUS Aortic Arch System, a meaningful regulatory win that could expand Artivion’s addressable market and support future growth. Artivion Reports First Quarter 2026 Financial Results and Announces Exercise of Option to Acquire Endospan
- Positive Sentiment: Artivion exercised its option to acquire Endospan, which may strengthen its aortic disease portfolio over time. Artivion Reports First Quarter 2026 Financial Results and Announces Exercise of Option to Acquire Endospan
- Neutral Sentiment: The company guided 2026 revenue to $480 million-$496 million, which is near Wall Street expectations but not a major upside surprise. Artivion Reports First Quarter 2026 Financial Results and Announces Exercise of Option to Acquire Endospan
- Negative Sentiment: Despite the beat-and-raise style quarter, investors appear focused on the stock’s rich valuation and the lack of a major guidance surprise, contributing to the selloff. Why is Artivion stock plummeting today?
- Negative Sentiment: Citizens JMP and Needham both lowered price targets, which may have added to the negative sentiment even though both firms kept bullish ratings. Benzinga report on lowered price targets
Artivion Company Profile
Artivion, Inc (NYSE: AORT) is a global medical technology company that develops, manufactures and markets implantable tissue products and surgical devices for cardiac and vascular surgery. The company’s portfolio includes biologic implants derived from human and animal tissue, such as allografts and xenografts, as well as synthetic scaffolds and surgical adhesives. These products are designed to repair, reinforce or replace damaged cardiovascular and thoracic tissues during procedures such as aortic repair, heart valve surgery and vascular reconstruction.
Originally founded in 1984 under the name CryoLife, the company rebranded as Artivion in early 2022 to reflect its broader mission in cardiovascular innovation.
See Also
Receive News & Ratings for Artivion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Artivion and related companies with MarketBeat.com's FREE daily email newsletter.
